Sarepta’s Gene Therapy Under Scrutiny After Patient Death
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, The Associated Press reported. However, the "severity" of this case had not been seen before, the company noted. Elevidys has been used in more than 800 patients, the company stated.
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
Investor's Business Daily on MSN1d
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback